

## Special Issue

# Hepatitis and Vaccines

### Message from the Guest Editor

The WHO has set elimination targets to achieve by 2030 to reduce the global burden of morbidity and mortality due to viral hepatitis. Prevention strategies, including vaccination, remain the cornerstone of this goal. There is a highly effective vaccine against the hepatitis B virus; however, timely delivery of the birth dose remains a major challenge worldwide. To overcome this hurdle, novel delivery devices and protocols such as delivery outside of the “cold chain” have been explored but not widely implemented. Currently, there is no effective vaccine available for hepatitis C, yet important work continues in this field. Advances in vaccine technology made through the development of vaccines against SARS-CoV-2 will further catalyze novel approaches to viral hepatitis vaccination development.

This Special Edition of *Vaccines* will cover topics relevant to vaccination in viral hepatitis, including novel vaccine delivery strategies, hepatitis C vaccine development, the role of therapeutic vaccines, and the modeled impact and cost-effectiveness of vaccination strategies to achieve viral hepatitis elimination.

---

### Guest Editor

Dr. Jessica Howell

1. Department of Gastroenterology, St Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia
2. Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia
3. Disease Elimination Program, Burnet Institute, Melbourne VIC, 3004, Australia
4. Department of Epidemiology and Preventive Medicine, Monash University, Clayton, VIC 3800, Australia

---

### Deadline for manuscript submissions

closed (31 October 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/88617](https://mdpi.com/si/88617)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).